Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225860 | 0.78 | CYP2D6 (0.52) | CYP2D6CYP2C19KCNH2CHRM2ADRA2A | |
| SCHEMBL29390583 | 0.78 | CYP2D6 (0.52) | CYP2D6CYP2C19KCNH2CHRM2ADRA2A | |
| SCHEMBL1921570 | 0.78 | CYP2D6 (0.62) | CYP2D6CYP2C19KCNH2CHRM2ADRA2A | |
| SCHEMBL2760196 | 0.77 | CYP2D6 (0.55) | CYP2D6CYP2C19KCNH2CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL28665181 | 0.77 | KDM4E (0.53) | CYP2D6CYP2C19KCNH2CHRM2ADRA2A | |
| SCHEMBL10806145 | 0.76 | ALDH1A1 (0.54) | KCNH2CHRM2ADRA2ADRD1SLC6A2 | |
| SCHEMBL7609146 | 0.76 | MAPT (0.55) | CYP2D6CYP2C19ALDH1A1HRH1SMN1; SMN2 | |
| SCHEMBL2217230 | 0.76 | — | — | |
| SCHEMBL29678128 | 0.76 | — | — | |
| SCHEMBL3589102 | 0.75 | CYP2D6 (0.48) | CYP2D6CYP2C19KCNH2CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020058062-A1 | HERBICIDALLY ACTIVE SUBSTITUTED PHENYLPYRIMIDINE HYDRAZIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-03-26 | — | — | WO | disclosed |
| CN-110709396-A | Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma | 伊文蒂瓦公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2010091543-A1 | NOVEL HYDRAZINO-CYCLOBUT-3-ENE-1, 2-DIONE DERIVATIVES AS CXCR2 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010091543-A1 | NOVEL HYDRAZINO-CYCLOBUT-3-ENE-1, 2-DIONE DERIVATIVES AS CXCR2 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-0113572-B1 | PYRIDINE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-02-03 | — | — | EP | disclosed |
| EP-0112704-B1 | PYRIDINE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-10-07 | — | — | EP | disclosed |
| US-4659725-A | 3-(2-pyridylaminoalkylamino)cyclobutenediones and pyridones useful as histamine H1 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-04-21 | — | — | US | disclosed |
| US-4607106-A | 3-(2-pyridylaminoalkylamino)thiazoles useful as histamine H1 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-08-19 | — | — | US | disclosed |
| US-4547506-A | 2-Pyridylaminoakylamino-4-pyrimidones useful as histamine H1 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-10-15 | — | — | US | disclosed |
| US-4532246-A | 2-(2-Pyridylaminoalkylamino)-4-pyrimidones | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-07-30 | — | — | US | disclosed |
| EP-0113572-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-07-18 | — | — | EP | disclosed |
| EP-0112704-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CYP2D6 2778/4885CYP2C19 2094/4885KCNH2 3871/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CYP2D6 2653/4885CYP2C19 1983/4885KCNH2 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.